[Hereditary angioedema due to C1-esterase inhibitor deficiency]

Revista De Medicina Interna, Neurologe, Psihiatrie, Neurochirurgie, Dermato-Venerologie. Medicina Interna
|September 1, 1989
PubMed

Insights

This study details hereditary angioedema due to C1-esterase inhibitor deficiency, appearing early in life with nasal and sinus symptoms. Crises were absent during pregnancy, and genetic analysis confirmed hereditary transmission across four generations.

Area of Science:

  • Immunology
  • Genetics
  • Medical Science

Background:

  • Hereditary angioedema (HAE) is a rare genetic disorder.
  • It is caused by a deficiency or dysfunction of the C1-esterase inhibitor (C1-INH).
  • HAE is characterized by recurrent episodes of severe swelling (angioedema).

Observation:

  • A case of familial angioedema due to C1-INH shortage presented in infancy (8 months).
  • Symptoms included nasal and sinus involvement, with prolonged localized edema lasting up to 9 days.
  • Angioedema attacks were notably absent during pregnancy.

Findings:

  • Genetic analysis of four generations revealed a predominantly hereditary pattern of transmission.
  • Two instances of apparent skipped generations in clinical manifestation were documented.
  • Early onset and specific symptomology (nasal/sinusal) were key characteristics.

Implications:

  • Understanding the hereditary nature of HAE is crucial for genetic counseling and family screening.
  • The absence of attacks during pregnancy suggests hormonal influences on HAE severity.
  • This case highlights the variability in HAE presentation and transmission patterns.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this barrier loses...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...